Latest News and Press Releases
Want to stay updated on the latest news?
-
WALTHAM, Mass., June 22, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically...
-
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...
-
LEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
-
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and...
-
-Grant Supports Health Economic Research Comparing In-House versus Send-Out dd-cfDNA Testing in Kidney Transplantation- NASHVILLE, Tenn., June 22, 2026 (GLOBE NEWSWIRE) -- Insight Molecular...
-
Genista launches refreshed brand, positioning Itself as the operating system for product safety — unifying testing, automation, software and services.
-
23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet Growth reflects both organic clinic initiatives and acquisition...
-
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage...
-
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to...
-
AUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More...